Background Checkpoint inhibitors have not been effective for prostate cancer as single
agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed …

Purpose: Prostate cancer translational research has been hampered by the lack of
comprehensive and tractable models that represent the genomic landscape of clinical …

Aberrations in epigenetic processes, such as histone methylation, can cause cancer.
Retinoblastoma binding protein 2 (RBP2; also called JARID1A or KDM5A) can demethylate …

Abstract Early growth response-1 (EGR1) is a transcription factor correlated with prostate
cancer (PC) progression in a variety of contexts. For example, EGR1 levels increase in …

Epigenetic regulation underlies the robust changes in gene expression that occur during
development. How precisely epigenetic enzymes contribute to development and …

The retinoblastoma tumor suppressor protein pRb restricts cell growth through inhibition of
cell cycle progression. Increasing evidence suggests that pRb also promotes differentiation …

Summary Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment
of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients …

Purpose: Irinotecan and topotecan are used to treat a variety of different cancers. However,
they have limitations, including chemical instability and severe side effects. To overcome …

Abstract The PI3K–AKT pathway has pleiotropic effects and its inhibition has long been of
interest in the management of prostate cancer, where a compensatory increase in PI3K …

The development of new treatments for castrate resistant prostate cancer (CRPC) must
address such challenges as intrinsic tumor heterogeneity and phenotypic plasticity …